<DOC>
	<DOC>NCT00191399</DOC>
	<brief_summary>The primary objective of this study is to assess the efficacy of olanzapine and fluoxetine combined on all the visits as compared with the baseline visit in patients with bipolar disorder, measured by the total score of the Montgomery-Asberg Depression Rating Scale (MADRS).</brief_summary>
	<brief_title>Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Meet criteria for bipolar depression, in the opinion of the investigator, according to the Diagnostic and Statistical Manual of Mental Disorders [Text Revision] (DSMIVTR) disease diagnostic criteria. Patients must have experienced, in the opinion of the investigator, at least one previous hypomanic, manic or mixed episode as defined in DSMIVTR. Subjects must have an initial score at Visit 1 of at least 20 on the MADRS. Any patient currently meeting DSMIVTR criteria rapidcycling course. A CGISeverity Mania score of at least 3.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>